SummaryA possible way to avoid dose-limiting side effects of platinum anticancer drugs is to employ light to cause photochemical changes in nontoxic platinum prodrugs that release active antitumor agents. This strategy could be used in the treatment of localized cancers accessible to irradiation (e.g., bladder, lung, esophagus, and skin). We report here that nontoxic photolabile diam(m)ino platinum(IV) diazido complexes inhibit the growth of human bladder cancer cells upon irradiation with light, and are non-crossresistant to cisplatin. Their rate of photolysis closely parallels that of DNA platination, indicating that the photolysis products interact directly, and rapidly, with DNA. Photoactivation results in a dramatic shrinking of the ca...
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that t...
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that t...
Photoactivatable agents offer the prospect of highly selective cancer therapy with low side effects ...
SummaryA possible way to avoid dose-limiting side effects of platinum anticancer drugs is to employ ...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
Photodynamic therapy that uses photosensitizers which only become toxic upon light-irradiation provi...
Novel all-trans dinuclear PtIV complexes bridged by a dicarboxylate linker, highly stable in the dar...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
The Pt IV diazido complex trans,trans,trans-[Pt(N 3) 2(OH) 2(pyridine) 2] (1) is unreactive in the d...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
Since the discovery of cisplatin, light activation has been employed as a strategy to switch and imp...
Diazido Pt(IV) complexes with a general formula [Pt(N3)2(L)(L′)(OR)(OR′)] are a new generation of an...
Photoactive platinum compounds have the potential to reduce some of the debilitating side-effects as...
Mono-axial functionalised octahedral diazido Pt(IV) complexes trans,trans,trans-[Pt(py)2(N3)2(OR1)(O...
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that t...
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that t...
Photoactivatable agents offer the prospect of highly selective cancer therapy with low side effects ...
SummaryA possible way to avoid dose-limiting side effects of platinum anticancer drugs is to employ ...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
Photodynamic therapy that uses photosensitizers which only become toxic upon light-irradiation provi...
Novel all-trans dinuclear PtIV complexes bridged by a dicarboxylate linker, highly stable in the dar...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
The Pt IV diazido complex trans,trans,trans-[Pt(N 3) 2(OH) 2(pyridine) 2] (1) is unreactive in the d...
Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from p...
Since the discovery of cisplatin, light activation has been employed as a strategy to switch and imp...
Diazido Pt(IV) complexes with a general formula [Pt(N3)2(L)(L′)(OR)(OR′)] are a new generation of an...
Photoactive platinum compounds have the potential to reduce some of the debilitating side-effects as...
Mono-axial functionalised octahedral diazido Pt(IV) complexes trans,trans,trans-[Pt(py)2(N3)2(OR1)(O...
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that t...
Photoactivatable Pt(IV) diazido complexes have unusual photobiologic properties. We show here that t...
Photoactivatable agents offer the prospect of highly selective cancer therapy with low side effects ...